Background. Primary Epstein-Barr virus (EBV) infection affects the host differently according to when in life it is acquired. Understanding risk factors for infection could be important for disease prevention, and the age-specific prevalence of infection must be known to optimize use of a prophylactic vaccine.
associated with elevated levels of EBV viremia throughout infancy, leading the investigators to speculate that these infants were at higher risk for endemic Burkitt lymphoma [12] [13] . A study found that Greenland Eskimo children acquired primary EBV infection at an earlier age and had higher titers of immunoglobulin G (IgG) antibody against EBV viral capsid antigen (VCA) than age-matched Danish children [3] . The authors speculated that early infection with "a large inoculum of EBV" explained why Eskimos were at high risk for nasopharyngeal carcinoma vs Danes who were not. Multiple sclerosis (MS) is another condition that may be triggered by early acquisition of EBV infection. A multinational study showed that children with MS were significantly more likely to be infected with EBV than matched controls [14] , and their antibody profiles were consistent with EBV infection months or years before the diagnosis of MS [15] . If early acquisition of primary EBV infection is a risk for chronic EBV-associated diseases, identifying and ameliorating those factors responsible for acquisition of the virus before adolescence may be an important public health step in disease prevention.
The first objective of this study was to determine the agespecific prevalence of EBV infection in children 18 months to 19.9 years of age, which is critical for deciding at what age to administer a prophylactic EBV vaccine. Our second objective was to define risk factors for acquiring EBV infection earlier in life, reasoning that if these could be modified, transmission of the virus to young children would be reduced. This Minnesota study provides important information not available in our report on samples from the National Health and Nutrition Examination Survey (NHANES) [4] , especially data on children <6 years of age and antibody concordance among siblings.
METHODS

Study Design
Subjects between the ages of 18 months and 19.9 years who had venous blood collected for medical indications at HealthPartners outpatient clinics in the Minneapolis-St Paul metropolitan area were eligible to participate. Children from families who gave informed consent and from whom adequate serum samples were available were tested for the presence and quantity of EBV antibodies. Data about family socioeconomics and demographics were obtained through telephone interviews. Questions included country of birth for the child and both parents, child's birth date and sex, race/ethnicity, adoption status, household income, parental education level, crowding, day-care attendance, and breastfeeding. This study was approved by the institutional review boards of HealthPartners and the University of Minnesota, and informed consent was obtained before participation.
EBV Antibody Prevalence
IgG antibodies against EBV VCA were measured using semiquantitative enzyme immunoassay (EIA) kits (Diamedix, Miami, Florida). A sample volume of 20 µL was used for each assay. Specimens, calibrators, and controls were prediluted 1:21 prior to placing them in the test wells. Cutoff calibrator, controls, and subject samples were diluted according to the specific test kit protocol, mixed briefly by vortex to assure good distribution of the sample in the diluent, and then transferred to the appropriately labeled wells and incubated. After washing the wells, conjugate was added with another incubation and a wash step followed. Substrate was added and allowed to incubate before the addition of stop/color reagent. The plates were read at an absorbance of 450 nm using a reference wavelength of 630 nm. EIA indices were calculated by hand using the formulas in the kit package insert. Data were recorded (1) as positive (EIA index ≥1.10), negative (EIA index <0.90), or equivocal (EIA index 0.90-1.09), and (2) as the exact numeric EIA index. All positive and negative EIA results were included in the data analysis. Equivocal samples were not tested further, and subjects with equivocal results were not included in the data analysis. 
Statistical Analysis
Demographic and Socioeconomic Comparisons
We report EBV antibody prevalence for non-Hispanic white children (n = 398), multiracial children (n = 117), nonHispanic black children (n = 93), Asian (n = 60), Hispanic (n = 34), and Native American (n = 3) children. Demographic factors and their effects were compared for non-Hispanic white, multiracial, and non-Hispanic black children, because sample sizes of the other 3 groups were too small for reliable estimates. Sex proportions, percentage adopted, and day-care attendance were similar for non-Hispanic white, multiracial, and non-Hispanic black children ( Table 1 ). The adjective "black" was specifically included in the parental description for 48% of multiracial children. Non-Hispanic black and multiracial children were more likely to be foreign-born and less likely to have been breastfed. There were significant differences in the age distribution of non-Hispanic white, multiracial, and nonHispanic black children as shown in Figure 1 and Table 1 . In addition, non-Hispanic black and multiracial children were more likely to live in conditions of high crowding and to have lower household income and lower household education, although at least 74% of parents in all 3 groups had completed some college (Table 1) .
Age-adjusted antibody prevalence differed significantly by race/ethnicity (Table 2) . It was lowest among non-Hispanic white children and highest among non-Hispanic blacks. EBV antibody prevalence increased significantly by age group, controlling for sex and race/ethnicity ( Table 2) . Abbreviations: GED, General Education Development; SD, standard deviation. a P value is overall comparison between the 3 groups.
b Duration of breastfeeding for those breastfed; duration of day-care attendance for those who attended.
The pattern of increases with age in EBV antibody prevalence differed significantly by race/ethnicity (Table 3 ). Age-specific curves diverged most noticeably between the age groups of 1.5-3 years and 4-5 years ( Figure 2 ). Adjusted EBV antibody prevalence decreased with greater household education among whites, but was not associated with child's sex, adoption status, birthplace, breastfed status, day-care attendance, or household income (Table 3) .
A comparison of EBV antibody prevalence in the 4 age categories (1-5, 6-9, 10-14, and 15-19 years) by race/ethnicity is shown in Table 4 . Non-Hispanic whites had a significantly lower antibody prevalence compared with non-Hispanic blacks in all 4 age categories. Non-Hispanic whites also had a significantly lower antibody prevalence as compared with multiracial children in all age categories except those 15-19 years old. Finally, multiracial children 10-14 years old had a significantly lower antibody prevalence compared with non-Hispanic blacks.
Familial Clustering of EBV Antibody Status
There were 51 families with 2 or 3 siblings enrolled in the study, for a total of 104 children. Siblings had the same EBV antibody status in 42 families, for a concordance of 82%. In 1000 simple random samples of the same size as the siblings from the study sample, chance concordance ranged from 27% to 71%, yielding a bootstrap P < .001 for observed concordance between siblings. The kappa measure of agreement for the siblings was κ = 0.65 (95% CI, .43-.86; P < .0001). There were 6 pairs of twins. All of them were same-sex and concordant for EBV antibody status (3 pairs were negative and 3 pairs were positive).
Country of Birth
Thirteen (14%) of 93 non-Hispanic black children were foreignborn, and 39 (42%) had foreign-born parents (all from Africa). Their antibody prevalence was higher but not statistically significantly different from the cohort of US-born non-Hispanic black children. Eleven of the 13 (85%) foreign-born children (median age, 9 years) were antibody positive vs 52 of 80 (65%) (median age, 9 years) born in the United States (P > .05, Fisher exact test). The 39 children (median age, 9 years) with African-born parents had an antibody prevalence of 74% (29/39) vs 63% (34/54) of non-Hispanic black children (median age, 9 years) born in the United States (P > .05, Fisher exact test). The number of non-Hispanic white or multiracial children born outside the United States or who had parents born outside the United States was too small to allow for a valid statistical analysis.
Antibody Prevalence by Clinic and Residential Location
Antibody prevalence by clinic for non-Hispanic whites, nonHispanic blacks, and multiracial children disclosed no statistically significant interclinic differences (data not shown). An analysis of 4 residential areas defined by ZIP codes (St Paul metropolitan, St Paul suburbs, Minneapolis metropolitan, and Minneapolis suburbs) also revealed no statistically significant differences between residential areas (data not shown).
Quantity of EBV EIA IgG Antibody
The EIA indices for the 300 antibody-positive subjects ranged from 1.34 to 7.35 (mean, 4.26; median, 4.73). The EIA indices had no relationship with race/ethnicity or age category especially as evidenced by the overlapping ranges (data not shown).
DISCUSSION
The most important finding of this study was the striking lower age-specific EBV antibody prevalence in non-Hispanic whites as compared with all other racial/ethnic groups. This difference was not due to country of birth for the child or the parents, child's sex, adoption status, residential location, household income, crowding, day-care attendance, or breastfeeding. The only socioeconomic factor associated with age-specific antibody prevalence was the level of parental education among nonHispanic white families.
The pattern of increases in antibody prevalence for nonHispanic whites, multiracial children, and non-Hispanic blacks diverged most noticeably in the age groups of 1.5-3 and 4-5 years ( Figure 2 ). In contrast, increases in antibody prevalence in the teenage groups were similar. Our interpretation of these observations is that a combination of genetics, family practices, and home environment were responsible for the racial/ethnic differences in antibody prevalence among young children. How the virus is transmitted to preadolescents is a mystery yet to be solved. Transmission of the virus during adolescence, usually by deep kissing [5] , occurred at similar rates among all racial/ethnic groups.
A 1967 report suggested that the incidence of clinical infectious mononucleosis among black US college students and military servicemen was much lower than that observed among whites [16] . Our data explain why. Infectious mononucleosis results from a primary EBV infection. The majority of nonHispanic black children, both in this study and in our NHANES report [4] , were antibody positive for EBV before adolescence and hence could not experience a primary EBV infection during the age period of highest risk for infectious mononucleosis.
EBV vaccines are in development [17] , and a prophylactic gp350 vaccine has been shown to reduce the incidence of infectious mononucleosis among young adults in Belgium [18] . The age-specific antibody data presented here and in the NHANES study could create a dilemma for vaccine policy if the strategy is to delay vaccination until the teenage years to provide A, B, C prevalence rates were compared separately between race/ethnicity groups, and between age groups. Rates with no letter in common were significantly different (P < .05), and rates sharing letters were not significantly different.
Abbreviation: CI, confidence interval. a Adjusted for age and sex, excluding 3 Native American children.
b Adjusted for race/ethnicity and sex, excluding 3 Native American children.
maximum protection for children at highest risk for infectious mononucleosis. If that is the decision and the goal is to vaccinate children before 50% of them acquire a primary EBV infection, the age to vaccinate would differ according to race/ethnicity. Our age-specific antibody prevalence data for Minneapolis-St Paul children tested in 2011-2012 indicate that non-Hispanic whites could be vaccinated in their teenage years, whereas nonHispanic blacks would need to be immunized before 6 years of age, and multiracial children before age 10. The target ages for vaccination might become older because the age-specific prevalence of EBV antibodies in the US population has been declining with time. The overall national age-adjusted EBV antibody prevalence among children 6-19 years of age declined from 72% in 2003-2004 to 65% in 2009-2010 [4] . In similar fashion, the antibody prevalence for 18-year-old University of Minnesota freshmen was 64% in 2006 and 62% in 2007 [5] . In 2012, it was 52% (H. H. Balfour Jr, unpublished observations). These data indicate that EBV antibody prevalence among US children and young adults is declining by 1%-2% per year.
On the other hand, if early acquisition of primary EBV infection is a risk for chronic EBV-associated diseases, and a number of published studies suggest that this is so [12] [13] [14] [15] , the logical policy would be to immunize all children between the ages of 15 months to 2 years. A report utilizing our NHANES laboratory dataset found that EBV VCA IgG EIA antibody indices were higher among nonHispanic black children as compared with non-Hispanic whites [19] . Higher levels of antibody were considered to indicate EBV reactivation that reflected impaired cell-mediated immunity. The authors regarded this as a racial disparity in immune function placing non-Hispanic black children at increased risk for additional infectious diseases, autoimmune disorders, and cancers. Their supposition could be correct but must be confirmed by additional data. As the authors themselves recognize, antibody levels are affected by time from primary infection to testing, and high levels may represent a recent primary infection rather than reactivation. Only a single sample from each subject was tested and thus the duration of elevated antibody levels could not be assessed. The risk for chronic EBV-associated diseases is most likely related to the duration of viral replication and the immune responses to it rather than to a single "spike" of viral activity [20] .
Familial clustering of EBV antibody status is a unique finding. Of 51 families with 2 or 3 subjects enrolled in the study, siblings had the same EBV antibody status in 42 families, for a concordance of 82% (P < .001). All 6 sets of same-sex twins were concordant for EBV antibody status (3 pairs were negative and 3 pairs were positive). Of interest is that a recent Danish study has elegantly documented a genetic basis for familial clustering of hospitalized cases of infectious mononucleosis [21] . Same-sex twins had a rate ratio of 9.3 for infectious mononucleosis, compared with 2.3 for first-degree relatives (opposite-sex twins, siblings, and parents). It is impossible to separate genetics from the environment as risk factors for EBV infection and its severity, but both are likely involved. If the severity of infectious mononucleosis has a genetic component, it is reasonable to speculate that the risk of acquiring the virus in the first place could also be under genetic control.
Non-Hispanic whites and non-Hispanic blacks had the most divergent EBV antibody prevalence. An intriguing finding of our study was that the age-and sex-adjusted EBV antibody Figure 2 . Epstein-Barr virus antibody prevalence by age group, adjusted for sex, with 95% confidence interval, for non-Hispanic white children (dark gray line), multiracial children (light gray line), and non-Hispanic black children (black line). Estimate for non-Hispanic black children aged 18-19 was omitted because the sample was too small. Abbreviations: CI, confidence interval; EBV, Epstein-Barr virus. prevalence was 57% in multiracial children whose parents included "black" in their racial/ethnic description. This is in between the prevalence of non-Hispanic blacks (74%) and nonHispanic whites (26%) and would be consistent with Mendelian inheritance governing susceptibility to early acquisition of EBV infection.
A limitation of our study is that it is a cross-sectional survey representative of a moment in time because we had only 1 sample per subject. However, EBV VCA IgG antibodies persist for life. Thus, the age-specific prevalence of EBV infection is accurate, except for possibly missing a few subjects who had been recently infected but had not yet developed an antibody response at the time of sampling. As mentioned above, the quantitative antibody data are not very reliable because they may fluctuate with time and also are affected by the period from acquisition of infection until testing.
Another limitation of our study is that our sample was not random. Children were selected because they made a visit to an outpatient clinic for medical indications. Of interest, however, was that the age-, sex-, and race/ethnicity-adjusted antibody prevalence was similar for the group whose visit was for an acute illness (40/100 [40%]) vs those who were not acutely ill (194/466 [42%]).
A final limitation is that Minneapolis-St Paul data may not pertain to other areas of the United States. However, its similarity to the NHANES data both in terms of the slopes of the age-specific antibody prevalence curves and the racial/ethnic disparities argue that it can be considered generally applicable.
In conclusion, age-specific prevalence of EBV infection was significantly lower among non-Hispanic whites vs other racial/ethnic groups. The lack of identifiable risk factors other than parental education level in non-Hispanic whites prompts us to speculate that genetics as well as shared environment play a role in the acquisition of primary EBV infection before adolescence. How preadolescent children acquire EBV is an important area for future research. Identifying and ameliorating those factors responsible for early infection may be an important public health step in disease prevention. Finally, our data indicate that early age of primary EBV infection among racial/ethnic groups other than nonHispanic whites is a health disparity that should be addressed.
Notes
